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Oxidative stress has emerged as a key component of many diseases that affect
the vasculature. Oxidative stress is characterized as a cellular environment where
the generation of oxidant molecules overwhelms endogenous anti-oxidant defense
mechanisms. NADPH oxidases are a family of enzymes whose primary purpose is
generation of reactive oxygen species (oxidant molecules) and therefore are likely to
be key contributors to oxidative stress. Hypertension is associated with oxidative stress
in the vasculature and is a major risk factor for stroke and cognitive abnormalities.
Angiotensin II (Ang II) is the main effector peptide of the renin-angiotensin system
(RAS) and plays a critical role in promoting oxidative stress in the vasculature. In the
cerebral circulation, Ang II has been implicated in reactive oxygen species generation,
alterations to vasomotor function, impaired neurovascular coupling, inflammation, and
vascular remodeling. Furthermore, studies in humans have shown that cerebral blood flow
is altered during hypertension and therapeutically targeting the RAS improves cerebral
blood flow. Importantly, many of the aforementioned effects have been shown to be
dependent on NADPH oxidases. Thus, Ang II, NADPH oxidases and oxidative stress are
likely to play key roles in the pathogenesis of hypertension and associated cerebrovascular
disease. This review will focus on our current understanding of the contribution of Ang II
and NADPH oxidases to oxidative stress in the cerebral circulation.
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INTRODUCTION
Hypertension is a highly prevalent disease throughout the world.
For example, it is currently estimated that 1 in 3 adults in the
United States has high blood pressure, which is defined as hav-
ing systolic blood pressure ≥140mmHg and/or diastolic blood
pressure ≥90mmHg, or being on medication to control their
blood pressure (Roger et al., 2011). Hypertension has profound
effects on the cerebral circulation and the brain and is a major
risk factor for both ischemic and hemorrhagic stroke as well
as cognitive abnormalities (Kivipelto et al., 2001; Lewington
et al., 2002; O’Donnell et al., 2010). Angiotensin II (Ang II)
is a pleiotropic peptide that has multiple effects on the cere-
bral vasculature. Importantly, Ang II plays a critical role in the
pathogenesis of hypertension. Two of the most effective anti-
hypertensive therapies, angiotensin converting enzyme (ACE)
inhibitors and angiotensin type 1 (AT1) receptor antagonists,
target key elements of the renin-angiotensin system (RAS). It
has also been established that hypertension causes oxidative
stress within the vasculature and Ang II is a key contributor
to this effect. Within the cerebral circulation, Ang II stimulates
the generation of reactive oxygen species (ROS) and has effects
on regulation of vascular tone as well as promoting inflam-
mation and changes to vascular structure. All of these effects
can influence cerebral blood flow. Either alone or in combina-
tion with other mechanisms, Ang II may underline many of the
deleterious effects of hypertension on the cerebral vasculature
and brain.
In the present review, we will consider recent evidence impli-
cating Ang II as a cause of oxidative stress specifically in the
cerebral circulation. As changes in cerebrovascular function may
ultimately impact cerebral blood flow, studies examining the
effects of hypertension on cerebral blood flow and the role of Ang
II and oxidative stress will also be discussed.
WHAT IS OXIDATIVE STRESS?
Oxidative stress is characterized by a shift from a cellular environ-
ment where the production andmetabolism of oxidant molecules
are tightly controlled to one of elevated levels of the same
molecules. The excess oxidant molecules may then overwhelm
anti-oxidant defense systems, resulting in oxidative stress. Such
a shift in balance can occur due to an overproduction of ROS,
such as superoxide (O2·−), or a reduction in the removal of
ROS by oxidant defense mechanisms. Key anti-oxidants include
O2·− dismutases (SOD), glutathione peroxidases, and catalase.
ROS can be generated by multiple enzymes within the vas-
culature as well as non-enzymatic sources. O2·− anion is the
parent ROS molecule produced by the one electron reduction
of molecular oxygen by various oxidases (e.g., NADPH oxidase,
cyclooxygenase, enzymes in the mitochondrial electron transport
chain, lipoxygenases, cytochrome P450 enzymes). O2·− can then
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be dismutated by SOD, resulting in the generation of hydro-
gen peroxide (H2O2; Figure 1). These ROS can undergo further
enzymatic or non-enzymatic reactions to generate other powerful
oxidant molecules, such as hydroxyl radical (OH·), peroxynitrite
(ONOO−), and hyperchlorous acid (HOCl) (Chrissobolis and
Faraci, 2008; Miller et al., 2010) (Figure 1).
Oxidative stress has been implicated in the pathogenesis of
many diseases that affect the cerebral circulation and the brain.
It is a fundamental component of aging as well as many dis-
eases including hypertension, hypercholesterolemia, atheroscle-
rosis, diabetes, stroke, and Alzheimer’s disease. One of the key
consequences of oxidative stress is impaired signaling of the
vasoprotective molecule nitric oxide (NO·), resulting in alter-
ations in vascular function and structure in addition to other
effects (Figure 1). Furthermore, oxidative stress contributes to
inflammation as well as damage to proteins, DNA and other
macromolecules. Thus, oxidative stress has wide implications for
overall cerebrovascular function and regulation. As such, it is no
surprise that there has been substantial effort devoted to under-
standing mechanisms that contribute to oxidative stress as well as
therapies to reduce oxidative damage.
FIGURE 1 | Interactions between nitric oxide (NO·) and reactive oxygen
species (ROS). NO· is a critical component of mechanisms that regulate
cerebrovascular homeostasis. Diverse stimuli (including shear stress,
neurotransmitters like acetylcholine and activation of neurons) can result in
the generation of NO· by either endothelial or neuronal nitric oxide synthase
(eNOS and nNOS, respectively). The generation of NO· is dependent on the
presence of the substrate L-arginine (L-Arg) and enzyme co-factors
including tetrahydrobiopterin (BH4). NO· activates its receptor in vascular
muscle soluble guanylate cyclase (sGC), which results in the formation of
cyclic guanosine monophosphate (cGMP). This results in numerous
signaling events and functional effects which include cerebral vasodilation.
NADPH oxidases (Nox1 and Nox2) generate superoxide (O2 ·−) and Nox4
can generate hydrogen peroxide (H2O2), ROS can then participate in
signaling events, but may also cause cellular injury. O2 ·− is a potent
scavenger of NO·, which reduces the bioavailability of NO· and results in
the formation of peroxynitrite (ONOO− ), which also causes cellular injury.
H2O2 can react with heavy metals to form the highly reactive and toxic
hydroxyl radical (OH·).
Many lines of evidence strongly indicate that oxidative stress
has damaging effects on vascular function. However, production
of ROS per se is not always detrimental as ROS sometimes have
beneficial effects within the vasculature. Specifically, some ROS
can function as vasodilators in cerebral arteries during physiolog-
ical conditions (Didion and Faraci, 2002; Park et al., 2004; Miller
et al., 2005, 2007a; Modrick et al., 2009) as well as during disease
(Paravicini et al., 2004; Kitayama et al., 2007). So, while elevated
levels of ROS contribute to oxidative stress including vascular
damage and dysfunction, lower levels of ROS may be important
signaling molecules for some vasoactive stimuli. Cerebral arter-
ies have the capacity to generate significantly higher levels of ROS
compared with systemic arteries (Miller et al., 2005, 2009). So,
while ROS may serve as an important signaling molecules and
vasodilators under physiological conditions, higher levels of ROS
may underlie the pathogenesis of disease in the cerebral circula-
tion. Therefore, to presumably avoid potentially harmful levels of
ROS, the production and metabolism of ROS are typically tightly
controlled.
The presence of oxidative stress has major implications for
cerebrovascular function. Oxidative stress has been implicated
in impaired cellular signaling, vascular remodeling, and inflam-
mation. Perhaps the best characterized mechanisms by which
oxidative stress can impair vascular function is via the disrup-
tion of endothelium-dependent NO· signaling. This mechanism
involves the chemical reaction between O2·− and NO·, one of
the fastest known biological reactions (Thomson et al., 1995),
approximately three times faster than the dismutation of O2·−
by SOD. Importantly, this reaction not only reduces the bioavail-
ability of NO·, but also simultaneously generates the highly toxic
reactive nitrogen species (RNS) ONOO−, which can have a num-
ber of damaging cellular effects (Figure 1). Thus, if levels are
increased locally, O2·− will rapidly react with and reduce the
bioavailability of NO·, resulting in oxidative stress. As NO· is a
key mediator of cerebral vasodilation driven by both endothe-
lium and neurons, alterations that reduce the bioavailability of
NO· would impair these responses (Figure 1).
WHAT ARE THE SOURCES OF ROS THAT CONTRIBUTE TO
OXIDATIVE STRESS?
A number of enzymes within the vasculature can be sources
of ROS, including xanthine oxidase (Kinugawa et al., 2005),
cyclooxygenases (Didion et al., 2001; Niwa et al., 2001), uncou-
pled NOS (Vasquez-Vivar et al., 1997, 1998; Landmesser et al.,
2003; Dikalova et al., 2010; Santhanam et al., 2012), and the
mitochondrial electron transport chain (Narayanan et al., 2010).
Several of these enzymes generate ROS as either a by-product of
normal enzyme activity or when the protein is in a dysfunctional
state. By contrast, NADPH oxidases are the only known family
of enzymes whose primary function is the generation of ROS
(Drummond et al., 2011). Thus, NADPH oxidases are candidates
for deliberate ROS production required for normal signaling and
for the excessive ROS associated with oxidative stress. It has also
been suggested that NADPHoxidase may serve as a source of ROS
that initiates a cascade of events including feed-forward mech-
anisms and recruitment of other enzymes that promote further
oxidative stress (Faraci, 2006; Selemidis et al., 2008).
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At present study, seven isoforms of NADPH oxidase have been
identified. These enzymes are named Nox1, Nox2, Nox3, Nox4,
andNox5 containing NADPHoxidases andDUOX1 andDUOX2.
In general, all NADPH oxidases generate O2 ·− by transferring
electrons from the substrate, NADPH, via the Nox catalytic
subunit to molecular oxygen. Nox1, Nox2, Nox4, and Nox5 con-
taining isoforms are all expressed within vascular cells, however,
to date only the Nox1, Nox2, and Nox4 containing isoforms have
been identified in the cerebral vasculature (Ago et al., 2005; Miller
et al., 2007a). Nox5 containing NADPH oxidase is not expressed
in rats and mice and as such, very little is known about this iso-
form and nothing in regards to any potential role in cerebral
arteries. Further studies, potentially including studies of genetic
models expressing Nox5 in vascular cells are needed to deter-
mine any potential contribution of this isoform to oxidative stress
in blood vessels supplying brain. Similarly, our understanding of
the expression and contribution, if any, of DUOX1/2 to oxidative
stress and vascular disease is extremely limited.
Many studies have implicated a role for NADPH oxidase-
derived ROS in models of cerebrovascular disease. As such, the
contribution of NADPH oxidases to Ang II-induced oxidative
stress will be the focus of this review. However, it is important
to remember that other oxidase enzymes and mechanisms may
also contribute to oxidative stress during disease.
NADPH OXIDASES
Here, we will briefly discuss some of the key features of the three
isoforms of NADPH oxidase that have been described within the
cerebral vasculature. The detailed structural and regulatory dif-
ferences between these enzymes have been discussed previously
and will not be discussed again here (Bedard and Krause, 2007;
Selemidis et al., 2008).
STRUCTURE OF NOX1, NOX2, AND NOX4 NADPH OXIDASE
The NADPH oxidase family of enzymes was discovered and ini-
tially studied in neutrophils, where Nox2 NADPH oxidase plays
a role in immunological host defense. Subsequently, Nox1, Nox2,
and Nox4NADPHoxidases were identified in vascular cells where
they are thought to play important roles under both physiological
and pathophysiological conditions (Miller et al., 2006).
Nox2 NADPH oxidase consists of two membrane-bound
subunits (Nox2 and p22phox), up to three cytosolic subunits
[p47phox (organizer subunit), p67phox (activator subunit) and
potentially p40phox] and the small G-protein Rac. The catalytic
domain resides in Nox2, which contains all of the necessary
components to facilitate the transfer of electrons from the sub-
strate, NADPH to molecular oxygen. Specifically, the catalytic
domain of Nox2 possesses two haem containing groups and a
FAD group, as well as a binding site for NADPH (Taylor et al.,
1993; Cheng et al., 2001). The p22phox subunit forms a het-
erodimer with Nox2 and contains a proline rich region that
facilitates the binding of p47phox with the membrane bound
subunits (Groemping et al., 2003). As such, p22phox plays a cru-
cial role in regulating Nox2 activity (Ambasta et al., 2004). In
unstimulated cells, Nox2 is dormant, and its activation requires
the interaction of Nox2/p22phox with the regulatory cytoso-
lic complex containing the p47phox and p67phox subunits.
During unstimulated conditions, p47phox is not associated with
the Nox2/p22phox complex due to the presence of an autoin-
hibitory domain which prevents the interaction of p47phox with
the proline rich region of p22phox (Groemping et al., 2003).
Translocation of p47phox to the membrane bound subunits is
dependent on protein kinase C (PKC)-dependent phosphory-
lation of serine residues on p47phox (Fontayne et al., 2002),
which results in a conformational change and displacement of
the autoinhibitory region on p47phox (Groemping et al., 2003).
p67phox binds to p47phox and this complex translocates to
the membrane where two SH3 domains on p47phox bind to
the proline rich region of p22phox (Groemping et al., 2003;
Nobuhisa et al., 2006). In addition, p47phox has also been shown
to bind multiple sites on Nox2, which is believed to be cru-
cial for the final assembly of the active oxidase (Deleo et al.,
1995). It has been suggested that the binding of Rac induces a
conformation change in p67phox, which in turn promotes its
binding to Nox2 (Sarfstein et al., 2004), which leads to a con-
formation change and electron flow through the Nox2 subunit
(Nisimoto et al., 1999). Much less is known regarding the role of
p40phox in the activation of Nox2NADPH.However, in coronary
endothelial cells isolated from p47phox-deficient mice, p40phox
may act as an alternative organizer subunit in the absence of
p47phox (Fan et al., 2009). Currently, it remains to be determined
if p40phox is necessary for Nox2 NADPH oxidase activation
in the cerebral circulation. The latter point notwithstanding,
once the Nox2 NADPH oxidase enzyme complex is assembled,
electrons can then be transferred from NADPH to FAD and
then to the haem groups and finally to molecular oxygen, thus
generating O2·−.
Nox1 NADPH oxidase is structurally similar to Nox2 NADPH
oxidase, but appears to utilize different regulatory cytosolic sub-
units for its activation. Like the Nox2 subunit, the Nox1 subunit
contains two haem groups, FAD and NADPH binding sites,
and forms a heterodimer with p22phox in the cell membrane
(Ambasta et al., 2004; Kawahara et al., 2005). Nox1 NADPH
oxidase is activated by NoxO1 (Nox organizer 1) and NoxA1
(Nox activator 1), which are homologs of p47phox and p67phox,
respectively (Banfi et al., 2003). While there is evidence that
Nox1 NADPH may be activated by p47phox and p67phox (Banfi
et al., 2003), the interaction of Nox1 with NoxO1/NoxA1 is
more effective than its interaction with p46phox/p67phox (Banfi
et al., 2003). It was recently shown that preventing Rac activation
by inhibiting PI3-kinase only attenuates Nox1 NADPH oxidase
activity by approximately 20% (Choi et al., 2008), suggesting that
it may not be critical for Nox1 NADPH oxidase activity. Unlike
p47phox, NoxO1 lacks an autoinhibitory domain and it has been
hypothesized that the Nox1 NADPH oxidase might be basally
active (Banfi et al., 2003). However, studies using Nox1 defi-
cient mice suggest that Nox1NADPHoxidase does not contribute
to O2·− production under basal conditions in cerebral arteries
(Jackman et al., 2009).
Nox4 NADPH oxidase was discovered in the kidney (origi-
nally named Renox) where it was proposed to serve as an oxy-
gen sensing enzyme (Geiszt et al., 2000). Similar to Nox1 and
Nox2 NADPH oxidase, the Nox4 catalytic domain contains all
of the required components for oxidase activity and forms a
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heterodimer with p22phox (Ambasta et al., 2004; Martyn et al.,
2006). However, one unique feature of Nox4 NADPH oxidase is
that it may not require cytosolic subunits or Rac for oxidase activ-
ity and may be basally active (Martyn et al., 2006). Also, Nox4
NADPH oxidase may preferentially generate H2O2, rather than
O2·− (Martyn et al., 2006; Schröder et al., 2012) (Figure 1).
EXPRESSION OF CEREBROVASCULAR NADPH OXIDASE
Our understanding of the expression profile of NADPH oxidase
isoforms in cerebral arteries lags behind that of systemic arteries.
However, it has been revealed that mRNA for the Nox1, Nox2,
and Nox4 catalytic subunits, p22phox as well as the cytosolic sub-
units p47phox, p67phox, NoxO1, and NoxA1, are expressed in
the rat basilar artery (Paravicini et al., 2004; Ago et al., 2005).
Furthermore, Nox1, Nox2, and Nox4 proteins are expressed in
cerebral arteries (Miller et al., 2007a). The specific cellular local-
ization of each Nox isoform is distinct. In the vasculature in
general, it is believed that Nox1, Nox2, and Nox4 are expressed in
endothelial cells, Nox1 and Nox4 are expressed in smooth mus-
cle cells and Nox2 and Nox4 expressed in adventitia (Drummond
et al., 2011). Indeed, using immunostaining, Nox1 was shown to
be present in all layers of the basilar artery (Ago et al., 2005).
Furthermore, using immunostaining and electron microscopy,
it has also been demonstrated that Nox2 protein is primarily
expressed in endothelial and adventitial cells of cerebral arteries
(Kazama et al., 2004; De Silva et al., 2009; Miller et al., 2009).
Nox4 immunostaining has been shown to be present throughout
the vascular wall (Kleinschnitz et al., 2010).
SUBCELLULAR LOCALIZATION OF NADPH OXIDASES IN CEREBRAL
ARTERIES
Very few studies have investigated the specific subcellular local-
ization of the different Nox isoforms in cerebral arteries. In rats
and mice, electron microscopy has been used to localize Nox2 to
the plasma membrane of endothelial cells (Kazama et al., 2004).
Furthermore, Nox2 immunoreactivity was also detected in the
cytoplasm of endothelial cells (Kazama et al., 2004), although
the exact subcellular structure where Nox2 was located was not
determined. While we currently lack further detail regarding the
intracellular localization of Nox isoforms in cerebral vessels, work
in cultured vascular cells has revealed differences in the localiza-
tion of the Nox isoforms. In cultured endothelial cells, diffuse
perinuclear staining for Nox1 was observed (Sipkens et al., 2011),
whereas in cultured vascular smooth muscle cells, Nox1 has been
shown to be expressed at the plasmamembrane, co-localized with
caveolae (Hilenski et al., 2004). Furthermore, Nox1 is expressed
in early endosomes in vascular smooth muscle cells (Miller et al.,
2007b). Nox2 protein was found in lipid raft rich fractions from
cultured endothelial cells (Zhang et al., 2006). Interestingly, in
endothelial cells, there is both evidence for (Li and Shah, 2002)
and against (Sipkens et al., 2011) perinuclear expression of Nox2.
Finally, Nox4 has been identified in the nucleus (Hilenski et al.,
2004; Kuroda et al., 2005) and the endoplasmic reticulum (Van
Buul et al., 2005; Chen et al., 2008; Lyle et al., 2009) in vascu-
lar smooth muscle and endothelial cells. In addition, Nox4 has
also been shown to be co-localized with focal adhesions in vas-
cular smooth muscle (Hilenski et al., 2004; Lyle et al., 2009).
While studies in cultured vascular cells are vital in our under-
standing of subcellular localization of the different isoforms of
NADPH oxidase, it is important that these findings are confirmed
in intact cerebral arteries.
EFFECTS OF ANG II ON CEREBROVASCULAR FUNCTION
GENERATION OF REACTIVE OXYGEN SPECIES
A well-known effect of exposure to Ang II in the vasculature is
increased generation of ROS. Acute Ang II treatment increases
ROS production by cerebral arteries from mice (Kazama et al.,
2004; De Silva et al., 2009; Jackman et al., 2009) and rats (Miller
et al., 2005). Furthermore, both Nox1 (Jackman et al., 2009)
and Nox2 (Kazama et al., 2004; De Silva et al., 2009) contribute
to Ang II stimulated ROS production as genetic deletion of the
catalytic subunit of either of these isoforms reduces Ang II stim-
ulated ROS production by cerebral arteries. In this regard, it
is interesting to note that in non-cerebral arteries from Nox1-
deficient mice, AT1 receptors fail to properly localize at the cell
membrane (Basset et al., 2009), suggesting that Nox1-derived
ROS may regulate expression of AT1 receptors at the cell sur-
face. While it remains to be established if this same pattern occurs
in cerebral vessels, it is conceivable that the attenuation in Ang
II-stimulated O2·− production found in cerebral arteries from
Nox1-deficient mice may actually be due to impaired traffick-
ing of the AT1 receptor to the cell membrane. The importance
of Nox4 in generating ROS in response to Ang II in cerebral arter-
ies is currently unknown. In addition to rapid effects in vitro,
acute systemic administration of Ang II increases cerebrovascu-
lar ROS levels. Using confocal microscopy, acute Ang II infusion
intravenously increased ROS production by cerebral blood ves-
sels in the cerebral cortex that was dependent on activation of
AT1 receptors and Nox2 NADPH oxidase (Girouard et al., 2006,
2007). Thus, acute in vitro or in vivo Ang II treatment increases
cerebrovascular NADPH oxidase-derived ROS. The majority of
evidence to date suggests Nox2 NADPH oxidase is the primary
source of Ang II-stimulated ROS in cerebral arteries. However,
there is some evidence to suggest that Ang II may also activate
Nox1 NADPH oxidase in cerebral blood vessels.
In addition to acute stimulation of ROS production, Ang II
elevates cerebrovascular ROS levels when administered more
chronically. For example, cerebrovascular O2·− production is ele-
vated following 7-days Ang II treatment. Specifically, both basal
and Nox2 stimulated O2·− production by cerebral arteries was
elevated following Ang II treatment (Chrissobolis et al., 2012).
Consistent with previous studies that have reported a key role
for Nox2 NADPH oxidase in Ang II-stimulated ROS production,
ROS production by cerebral arteries from Nox2 deficient mice
treated with Ang II was not elevated (Chrissobolis et al., 2012).
In support of these findings, studies using genetically altered
mice with life-long Ang II-dependent hypertension also suggest
that increased O2·− underlies impaired endothelial function in
cerebral arteries (Faraci et al., 2006).
In another model of chronic Ang II-dependent hypertension,
using a lower dose of Ang II to produce a delayed increase in blood
pressure (also known as a “slow-pressor” dose of Ang II), ROS
levels in the vasculature are elevated (Capone et al., 2010, 2011,
2012). Specifically, using dihydroethidium fluorescence (to detect
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ROS) and immunofluorescence (to stain for cell-specific mark-
ers), increases in ROS levels were localized to the endothelium
as well as neurons. This elevation in ROS was associated with
impaired cerebrovascular responses to endothelium-dependent
agonists (Capone et al., 2011, 2012). Scavenging O2·− reduced
ROS levels and ameliorated the impaired vasodilation, indi-
cating that the increases in O2·− were functionally important
(Capone et al., 2011). Using this same model, Ang II infusion
produced an increase in oxidative stress within the subfornical
organ (SFO) (Capone et al., 2012), a specialized circumventric-
ular organ which can sense changes in plasma Ang II levels
and participates in central mechanisms that promote hyperten-
sion. Increased oxidative stress in the SFO paralleled increases in
circulating arginine vasopressin (AVP) and increased perivascu-
lar concentrations of endothelin-1 (ET-1) (Capone et al., 2012).
Ultimately, both ET-1 and Ang II mediated the elevation in ROS
in the vasculature (Capone et al., 2012), presumably via activa-
tion of Nox2 NADPHoxidase. Overall, this recent study suggested
that the SFO, though effects on AVP and ET-1, contributes to Ang
II-induced oxidative stress.
ALTERATIONS TO CEREBROVASCULAR FUNCTION
In addition to being a strong stimulus of NADPH oxidase activ-
ity, Ang II is a potent vasoconstrictor. Studies of cerebral arteries,
including those in humans, have found that Ang II produces vaso-
constriction (Whalley et al., 1985, 1987; Toda et al., 1990; Bevan
et al., 1998; Stenman and Edvinsson, 2004; Miller et al., 2005;
Vincent et al., 2005; Faraci et al., 2006; De Silva et al., 2009;
Amberg et al., 2010; Ahnstedt et al., 2011). Both genetic and
pharmacological approaches have established that Ang II induces
constriction of cerebral arteries via activation of AT1 receptors
(Naveri et al., 1994; Stenman and Edvinsson, 2004; Faraci et al.,
2006). Classical Ang II-induced contraction of smooth muscle
occurs via AT1 receptor mediated activation of phospholipase C,
resulting in inositol 1,4,5-triphosphate (IP3) and diacylglycerol
(DAG) production. IP3 and DAG regulate two distinct pathways,
however, both ultimately result in smooth muscle contraction via
activation of a number of protein kinases, such as myosin light
chain kinase and Rho-kinase (Hilgers and Webb, 2005). Indeed,
Ang II-induced constriction of basilar arteries is abolished in the
presence of the Rho-kinase inhibitor, Y-27632 (Faraci et al., 2006).
While some effects of Ang II can clearly be mediated by
AT1 receptors on vascular muscle, double-label immunoelec-
tron microscopy and other approaches have demonstrated that
AT1 receptors are also present in cerebral endothelium where
Ang II can produce endothelium-dependent constriction via
cyclooxygenase- and/or O2·−-dependent mechanisms (Manabe
et al., 1989; Kazama et al., 2004; De Silva et al., 2009). As noted
above, ROS are important modulators of vascular tone and Ang
II-induced constriction of cerebral arteries in mice are mediated
by H2O2 (De Silva et al., 2009). Considering this and the afore-
mentioned findings together, it is possible that Ang II-induced
constriction of cerebral arteries occurs via stimulation of ROS
production, which in turn leads to the activation of Rho-kinase.
While Rho-kinase is not generally thought to be a redox sen-
sitive enzyme, the activity of the small G-protein RhoA, the
principal activator of Rho-kinase, is redox-sensitive and thus may
be modulated by ROS. Indeed, both O2·− and t-butyl hydroper-
oxide (a stable analog of H2O2) can activate RhoA (Jin et al., 2004;
Jernigan et al., 2008; Aghajanian et al., 2009; Broughton et al.,
2009). Specifically, oxidation of two cysteine residues in the phos-
phoryl binding loop of RhoA by t-butyl hydroperoxide results
in the exchange of guanosine diphosphate (GDP) for guanosine
triphosphate (GTP), and activation of RhoA (Aghajanian et al.,
2009). Once active, RhoA then translocates to the cell mem-
brane where it binds to and activates Rho-kinase (Leung et al.,
1995). This may result in signaling via the well-established path-
way of Rho-kinase-dependent inhibition of myosin light chain
phosphatase (MLCP), thus preventing the de-phosphorylation
of myosin (Kimura et al., 1996; Jin et al., 2004; Jernigan et al.,
2008). While this may be a potential signaling pathway by which
Ang II induced constriction in cerebral arteries, further stud-
ies are needed to clarify the role of ROS in vascular responses
to Ang II.
In addition to direct effects on vasomotor tone, Ang II
impairs endothelium-dependent vasodilation by reducing the
bioavailability of NO· and potentially by interfering with other
endothelium-dependent mechanisms. This effect is intimately
linked with the increased production of ROS (mainly O2·−)
in response to Ang II and resulting impairment of NO·-
mediated signaling (Figure 2). Consistent with this concept,
numerous studies indicate that Ang II has deleterious effects
on cerebrovascular function. Indeed, in multiple models (both
FIGURE 2 | Angiotensin II (Ang II) promotes oxidative stress in the
vasculature via stimulation of AT1 receptors and subsequent
activation of NADPH oxidases. Oxidative stress contributes to blood-brain
barrier (BBB) dysfunction, impairment of vasodilation and neurovascular
coupling, and promotes inward vascular remodeling and inflammation.
Overall, these effects contribute to reductions in cerebral blood flow, which
can lead to dementia and increased susceptibility for stroke and lessen
recovery following stroke or other forms of brain injury.
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acute and chronic administration) (Gerzanich et al., 2003; Faraci
et al., 2006; Kitayama et al., 2006; Chrissobolis and Faraci, 2010;
Chrissobolis et al., 2012), Ang II impairs endothelium-dependent
vasodilation cerebral blood vessels. Treatment with scavengers of
O2·− improved endothelial function, thus indicating that oxida-
tive stress played a key role in producing this dysfunction (Faraci
et al., 2006; Kitayama et al., 2006; Chrissobolis and Faraci, 2010).
A recent study has provided, further evidence supporting a role
for NADPH oxidase-derived ROS in causing oxidative stress in
response to Ang II treatment. Specifically, 7-days Ang II treatment
did not result in impaired endothelium-dependent vasodilatation
in arteries from Nox2 deficient mice (Chrissobolis et al., 2012).
This same study reported a small role for the Nox1-containing
NADPH oxidase in this model of Ang II-induced dysfunction
(Chrissobolis et al., 2012). Further studies will be needed to better
define the role of this isoform of NADPHoxidase as well as Nox4-
and Nox5-containing NADPH oxidase in hypertension as well as
other disease states.
EFFECTS ON NEUROVASCULAR COUPLING
Many cell types including vascular muscle and endothelial cells,
neurons and glia work together to supply oxygen and glucose to
support the dynamic energy demands of the brain. This interac-
tion between the cells within the parenchyma has given rise to
the concept of a “neurovascular unit,” a multi-cellular structure
with unique features and functions. For example, cells within the
neurovascular unit are part of one segment of the circulation that
contributes to regulation of cerebral blood flow during changes in
metabolic demands that result from increased brain activity. This
relationship between cellular activity and local cerebral blood
flow is often termed neurovascular coupling or functional hyper-
emia. Cellular activity increases the need of brain cells for oxygen
and nutrients, as well as the removal of metabolic by-products by
the circulating blood. Specifically, when neurons and/or glia are
active and require more energy substrates, the release of paracrine
factors and other mechanisms produce dilation of local cerebral
arterioles and upstream vessels supplying the region resulting in
an increase in local cerebral blood flow. Several factors have been
suggested to mediate the neurovascular coupling response. NO·
(Iadecola et al., 1995; Liu et al., 2008), K+ ions (Filosa et al.,
2006), arachidonic acid metabolites (Niwa et al., 2000; Liu et al.,
2008) as well as products of cellularmetabolism such as adenosine
(Dirnagl et al., 1994; Meno et al., 2001) have all been proposed to
contribute to neurovascular coupling. These factors are release by
neurons/glial cells and activate receptors/ion channels on cerebral
blood vessels leading to vasodilation and a subsequent increase
in local cerebral blood flow. It has also been suggested that the
identity of the factor(s) mediating the neurovascular coupling
response is dependent on the brain region and multiple agents
may act in concert to produce the full vasodilatory response
(Iadecola and Nedergaard, 2007).
Neurovascular coupling is affected by both Ang II and oxida-
tive stress (Figure 2). Both acute and chronic systemic adminis-
tration of Ang II increases arterial blood pressure. Irrespective of
the length of treatment, Ang II-induced hypertension was associ-
ated with impairment of the neurovascular coupling response to
whisker stimulation (Kazama et al., 2003, 2004; Girouard et al.,
2007, 2008; Capone et al., 2009, 2010, 2011). Interestingly, in
mice that were administered phenylephrine acutely to produce a
similar degree of hypertension, there was no impairment of neu-
rovascular coupling (Kazama et al., 2003; Capone et al., 2011),
suggesting that Ang II and not the elevation in systemic pres-
sure per se caused the neurovascular dysfunction. This impaired
neurovascular coupling could be restored to normal by treat-
ment with O2 ·− scavengers (Kazama et al., 2004; Capone et al.,
2011), suggesting a key role for oxidative stress. Further stud-
ies indicated that Nox2 NADPH oxidase was the likely source of
increased ROS as Nox2-deficient mice were protected from Ang
II-dependent neurovascular dysfunction (Kazama et al., 2004;
Girouard et al., 2007). Ang II has also been shown to increase
3-nitrotyrosine immunoreactivity (a marker for ONOO− forma-
tion), in a Nox2 NADPH oxidase-dependent manner in cerebral
vessels (Girouard et al., 2007), suggesting that Ang II-dependent
hypertension causes oxidative stress and vascular dysfunction
within components of the neurovascular unit. Furthermore, it
was also shown that a ONOO− scavenger or a ONOO− decom-
position catalyst protect against Ang II dysfunction (Girouard
et al., 2007). These findings suggest that ONOO− may be
a key intermediate of neurovascular dysfunction in response
to Ang II.
The presence of the blood-brain barrier (BBB) is a unique
characteristic of cerebral blood vessels with many functions
including regulation of influx and efflux of cells and molecules
between the blood and the brain. There is emerging evidence
that Ang II and oxidative stress have detrimental effects on BBB
permeability (Figure 2). For example, Ang II increases the per-
meability of cerebral microvascular endothelial cells in culture
(Guillot and Audus, 1991; Fleegal-Demotta et al., 2009), which
may contribute to increases in BBB permeability in vivo. Indeed,
studies of Ang II-dependent hypertensive mice have found that
BBB permeability is increased compared with vehicle treated mice
(Vital et al., 2010; Zhang et al., 2010). Feeding of a high salt diet to
Ang II treated mice did not augment BBB permeability, suggest-
ing that Ang II and not increases in arterial pressure per se was
the mediator of BBB dysfunction (Vital et al., 2010). Along these
lines, DOCA (deoxycorticosterone acetate)/salt-induced hyper-
tension is not associated with increased blood brain barrier
permeability (Rodrigues and Granger, 2011). Oxidative stress is
likely to be a keymediator of BBB dysfunction as treatment of Ang
II-dependent hypertensive mice with a O2·− scavenger prevents
BBB dysfunction (Zhang et al., 2010). The source of ROS and the
mechanisms by which BBB permeability is increased during Ang
II-dependent hypertension remains unclear. However, consider-
ing that Nox1 andNox2NADPHoxidase are important sources of
Ang II-stimulated ROS in the cerebral circulation, these enzymes
may play a key role.
ALTERATIONS TO VASCULAR STRUCTURE
One of the mechanisms that can contribute to vascular dys-
function and impact cerebral blood flow is alterations to the
structure of cerebral arteries and arterioles. Hypertension is
associated with hypertrophy of large conduit vessels, such
as the aorta, whereas it causes inward remodeling of smaller
resistance vessels, including cerebral arterioles (Figure 2;
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Baumbach and Heistad, 1989; Baumbach et al., 2003). This latter
structural change results in a smaller diameter lumen even when
the vessel is maximally dilated (Baumbach and Heistad, 1989;
Baumbach et al., 2003) and has emerged as a potential risk factor
for cardiovascular and cerebrovascular events (Faraci, 2011).
Ang II appears to be a critical mediator of inward remodeling
as cerebral arterioles undergo remodeling and hypertrophy in
Ang II-dependent models of hypertension, whereas Ang II-
independent hypertension only causes hypertrophy (Baumbach
et al., 2003). Furthermore, preliminary studies suggest Nox2
NADPH oxidase may be the critical link between Ang II and
inward remodeling as cerebral arterioles from Nox2 deficient
mice do not undergo inward remodeling following Ang II infu-
sion (Chan and Baumbach, 2009). Inward remodeling impairs
vasodilator capacity and thus can compromise brain perfusion
and may contribute to impaired cognitive function in people
with hypertension.
CEREBROVASCULAR INFLAMMATION
Hypertension induces an inflammatory phenotype within the
cerebral vasculature and Ang II is believed to be a key mediator
of this effect (Figure 2). For example, spontaneously hyperten-
sive rats (SHR) have elevated expression of the pro-inflammatory
marker intercellular adhesion molecule 1 (ICAM-1) (Ando et al.,
2004). Interestingly, treatment of SHR with an AT1 receptor
antagonist reduced the expression of ICAM-1, indicating a key
role for Ang II (Ando et al., 2004). The increased expression of
this adhesion molecule was associated with increased adhesion
and infiltration of macrophages into the brain of SHR (Ando
et al., 2004). As with ICAM-1 expression, treatment with an
AT1 receptor antagonist prevented the increased macrophage
infiltration (Ando et al., 2004). More recently, it has been demon-
strated that there is an increase in leukocyte and platelet adhe-
sion to the microvasculature in Ang II-induced hypertension
(Vital et al., 2010; Zhang et al., 2010). The increased leuko-
cyte/platelet adhesion observed during Ang II-induced hyperten-
sion is dependent on AT1 receptors on leukocytes/platelets (Vital
et al., 2010) and ROS (Zhang et al., 2010), indicating that oxida-
tive stress may play a key role. Similarly, in a DOCA/salt model
of hypertension, leukocyte and platelet adhesion is dependent
on activation of AT1 receptors and mitochondrial-derived ROS
(Rodrigues and Granger, 2011). The source of the ROS contribut-
ing to augmented leukocyte and platelet adhesion to the cere-
bral microvasculature warrants further investigation. However,
due to the link between AT1 receptors and Nox2 NADPH oxi-
dase, it is possible that this isoform of NADPH oxidase plays a
key role.
SEX-DEPENDENT DIFFERENCES IN CEREBROVASCULAR RESPONSES
TO ANG II
It is well-known that the incidence of cerebrovascular disease is
lower in pre-menopausal females compared with males and post-
menopausal females (Prencipe et al., 1997; Appelros et al., 2009).
At present study, the precise reasons for the sex-dependent dif-
ferences in disease incidence remain to be fully defined. However,
the fact that Ang II has sexually dimorphic effects on the cere-
bral vasculature may contribute to the observed difference in
disease incidence. Acute Ang II treatment increases O2·− and
H2O2 levels to a greater extent in arteries from males compared
with females (De Silva et al., 2009). Indeed, sex differences
in Ang II stimulated ROS was completely dependent on Nox2
NADPH oxidase (De Silva et al., 2009). This effect is consis-
tent with other previous reports that have shown that Ang II
exerts sexually dimorphic effects with regards to vasoconstric-
tion (Faraci et al., 2006) and susceptibility to vascular dysfunction
(Girouard et al., 2008; Chrissobolis and Faraci, 2010). This effect
of sex on cerebrovascular ROS levels, vasoconstriction and neu-
rovascular dysfunction in response to Ang II is likely due to
the protective effects of estrogen on the cerebral circulation.
Specifically, cerebrovascular ROS levels in response to Ang II are
only elevated during diestrus (low estrogen levels) and Ang II
does not significantly elevate ROS levels during proestrus and
estrus (Capone et al., 2009). Due to the increase in oxidative
stress, female mice in diestrus were susceptible to Ang II-induced
neurovascular dysfunction (Capone et al., 2009). Currently, the
mechanisms by which estrogen suppresses Ang II-induced oxida-
tive stress in the cerebral circulation remains to be determined.
If therapies are developed that can exploit this phenomenon, it
may prove to be an effective therapy to reduce cerebrovascular
oxidative stress.
EFFECTS ON CEREBRAL BLOOD FLOW IN HUMANS
Hypertension has detrimental effects on cerebral blood flow in
humans (Lipsitz et al., 2005; Beason-Held et al., 2007; Dai et al.,
2008; Efimova et al., 2008; Nagata et al., 2010; Waldstein et al.,
2010; Muller et al., 2012). Hypertension is associated with a
shift in the autoregulatory curve to the right (Cipolla, 2007;
Iadecola and Davisson, 2008). This means that during hyperten-
sion, higher pressures are needed to maintain cerebral perfusion
in the normal range. Therefore, an aggressive blood pressure low-
ering regime may result in cerebral hypoperfusion and adverse
outcomes. Despite the aforementioned concerns, a number of
experimental studies have reported that anti-hypertensive thera-
pies that target the RAS improve cerebral blood flow. As discussed
above, Ang II has a number of diverse effects on the cerebral cir-
culation, including effects on vascular tone, which may lead to
reductions in cerebral blood flow (Figure 2). As such, it is not sur-
prising that treatment with either ACE inhibitors (Lipsitz et al.,
2005; Efimova et al., 2008) or AT1 receptor antagonists (Oku
et al., 2005; Kimura et al., 2010; Nagata et al., 2010; Muller et al.,
2012) improves or maintains total cerebral blood flow in hyper-
tensive patients. Recently however, the Second Manifestations
of ARTerial disease-Magnetic Resonance (SMART-MR) study
reported that despite effective treatment (reduction of BP to
<140/90mmHg) neither ACE inhibitors or other non RAS based
therapies (β-blocker, diuretic or calcium channel blocker) pre-
vented the decline in cerebral blood flow that occurs in elderly
hypertensive individuals over an average 3.9 years follow up
period (Muller et al., 2012). In contrast, effective treatment (BP
<140/90mmHg) of hypertensive patients with an AT1 receptor
antagonists prevented the decline in cerebral blood flow (Muller
et al., 2012). The inability of ACE inhibitors to improve cere-
bral blood flow may suggest that AT1 receptor antagonism pro-
vides additional benefits over reducing circulating Ang II levels.
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One possibility is that inhibition of AT1 receptors allows circulat-
ing Ang II to signal via AT2 receptors. AT2 receptor activation has
a number of potential beneficial effects on the vasculature, many
of which oppose with effects of AT1 receptor activation (e.g.,
vasodilatation). As oxidative stress is a central component of Ang
II-induced cerebrovascular dysfunction it would be expected that
oxidative stress contributes to changes in cerebral blood flow dur-
ing hypertension. However, further studies are needed to clarify
whether oxidative stress plays a role in alterations to cerebral per-
fusion associated with hypertension in humans and which class of
therapeutics would be of most benefit in reducing hypertension,
while maintaining cerebral perfusion.
Increases in blood flow produce flow-mediated (or flow-
dependent) dilation of cerebral arteries in rats in vivo (Fujii et al.,
1991, 1992; Paravicini et al., 2006). A similar dilator mechanism
appears to be present in humans and may be impacted by hyper-
tension. For example, hypertension impairs increases in cerebral
blood flow caused by mental stress (Naqvi and Hyuhn, 2009).
Dilation of the common carotid artery as well as increases in
blood flow velocity in the middle cerebral artery in response
to mental stress are selectively impaired in hypertensive patients
compared with normotensive controls (Naqvi and Hyuhn, 2009).
These findings in humans are consistent with studies in ani-
mal models which suggest that hypertension impairs neurovas-
cular coupling and mechanisms that provide critical support
for functional hyperemia responses (flow-mediated dilation of
large upstream vessels with the resulting maintenance of local
microvascular pressure). If Ang II and oxidative stress similarly
contribute to the impaired neurovascular coupling, therapeuti-
cally targeting the RAS may be of benefit.
CONCLUSION
Ang II has prominent effects on the cerebral circulation. Many
of these effects are deleterious and occur as a result of oxida-
tive stress and the accompanying vascular dysfunction. Overall,
the dysfunction caused by Ang II may result in compromised
cerebral perfusion and may ultimately predispose the brain
the hypoperfusion-dependent cognitive abnormalities as well as
ischemic events. The vast majority of experimental studies to date
implicate Nox2 NADPHoxidase-derived ROS as the major source
of O2·− and thus a key mediator of Ang II-induced oxidative
stress. Due to the sensitivity of cerebral arteries to ROS, alterations
to cerebrovascular function in response to Ang II may occur prior
to changes in other parts of the vasculature. As such, additional
studies that further define the role of Ang II and oxidative stress
in the pathogenesis of cerebrovascular diseases will prove crucial.
Furthermore, identification of molecules that protect the cere-
bral circulation and the brain against the effects of Ang II and
oxidative stress may be of substantial benefit.
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